Abstract
Number-needed-to-treat (NNT) and cost data were combined to assess the cost-effectiveness of branded disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS), and compare the incremental healthcare costs per relapse avoided and healthcare cost savings of ozanimod with commonly used oral and injectable DMTs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
